详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer(Open Access)

116| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]State Key Laboratory of Oral Diseases, Department of Oral Pathology, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China [2]Department of Head and Neck Surgery, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, China [3]State Key Laboratory of Microbial Technology, Shandong University, Qingdao, China

出处：

DOI：

ISSN：

关键词： head and neck immunotherapy PD-1 PD-L1 prognostic

摘要：

Over the past 10 years, cancer immunotherapy has made significant progress in multiple cancer types and has been gradually been applied to clinical cancer care, in which the programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway is one of the most attractive targets. Compared with traditional therapies, the emerging PD-1/PD-L1 blockade immunotherapy exhibited more satisfactory curative effects and lower toxicity for patients with advanced head and neck squamous cell carcinoma (HNSCC). This review analyzes the expression characteristics and clinical significance of PD-1/PD-L1 in HNSCC, the immunosuppressive roles of tumor cell and stromal cell expressing PD-1/PD-L1 in this disease, and presents the development landscape of PD-1/PD-L1 inhibitors, which may provide new curative alternatives for recurrent or metastatic HNSCC. © Copyright © 2020 Qiao, Jiang, Pang, Huang, Tang, Liang and Tang.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 2 区

医学

小类 | 3 区免疫学

最新[2023]版：

大类 | 2 区医学

小类 | 2 区免疫学

JCR分区：

出版当年[2020]版：

Q1 IMMUNOLOGY

最新[2023]版：

Q1 IMMUNOLOGY

影响因子： 5.7 最新[2023版] 6.8 最新五年平均 7.561 出版当年[2020版] 7.624 出版当年五年平均 5.085 出版前一年[2019版] 8.787 出版后一年[2021版]

第一作者：

第一作者机构： [1]State Key Laboratory of Oral Diseases, Department of Oral Pathology, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]中国PD-1/PD-L1抑制剂治疗肺癌临床试验概况 [2]PD-1/PD-L1在食管鳞状细胞癌中的表达及临床意义 [3]PD-1/PD-L1在肝细胞癌治疗中的研究进展 [4]PD-1/PD-L1抑制剂在妇科肿瘤的研究进展 [5]PD-1/PD-L1与食管鳞癌治疗和预后的相关性研究进展 [6]Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation [7]Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy [8]PD-1/PD-L1与食管鳞癌治疗和预后的相关性研究进展 [9]PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study [10]A PD-1 /PD-L1 proximity assay as a theranostic marker for PD-1 blockade in patients with metastatic melanoma.